* Tandem Diabetes Care Inc TNDM.OQ TNDM.O is expected
to show
a rise in quarterly revenue when it reports results on May 2
for the period ending March 31 2024
* The San Diego California-based company is expected to
report a
2.7% increase in revenue to $174.022 million from $169.38
million a year ago, according to the mean estimate from 16
analysts, based on LSEG data.The company's guidance on February
21 2024, for the period ended March 31, was for revenue of
$175.000 million.
* LSEG's mean analyst estimate for Tandem Diabetes Care Inc
is
for a loss of 76 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Tandem
Diabetes
Care Inc is $39.50, above its last closing price of $37.05.
The company's guidance on February 21 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of of USD-25.5 million.The company's guidance
on February 21 2024 for the period ended March 31 was for gross
profit margin of USD48%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.28 -0.25 -0.27 Missed -6
Sep. 30 2023 -0.36 -0.34 -0.38 Missed -13
Jun. 30 2023 -0.53 -0.53 -0.55 Missed -3.4
Mar. 31 2023 -0.55 -0.52 -1.92 Missed -271.6
Dec. -0.06 -0.06 -0.25 Missed -339.2
31 2022
Sep. 30 2022 -0.05 -0.05 -0.27 Missed -455.3
Jun. 30 2022 0.02 0.03 -0.24 Missed -850
Mar. 31 2022 -0.04 -0.06 -0.23 Missed -296
This summary was machine generated April 30 at 20:23 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)